In 2021, Taiji Group Co., Ltd. (Taiji Group for short, stock code: 600129), whose history could be dated back to 1972, accomplished a strategic restructuring, becoming a member of China National Pharmaceutical Group Co., Ltd.(Sinopharm for short), one of the Fortune Global 500 company.
Taiji Group mainly engages in the intelligent manufacturing of modern Chinese medicine, supplemented by stupefacient and psychotropic drugs. As an important part of Sinopharm's modern Chinese medicine division, Taiji Group is committed to the inheritance and innovation of traditional Chinese medicine and the development of modern Chinese medicine.
Taiji Group owns 13 pharmaceutical factories, more than 20 pharmaceutical commercial companies, two pharmaceutical research institutes, more than 3,000 chain pharmacies mainly based in Sichuan and Chongqing，with 13,000 employees and a full chain mainly covering pharmaceutical research and development, industrial production, pharmaceutical sales and big health industry.
Taiji Group has been consecutively rated as a "Top 100 Pharmaceutical Enterprise in China" by the Ministry of Industry and Information Technology. In 2019, Taiji Group won the title of "National Intellectual Property Model Enterprise". In the China Pharmaceutical Brand Value Ranking 2021 released by Brand Finance, an authoritative international brand value consulting company, Taiji Group ranked 13th. Taiji Group has earned the "Industrialization-Informatization Integration Management System" certification by the Ministry of Industry and Information Technology. The TCM Extraction Center has passed the technical review by the Ministry of Industry and Information Technology as a pharmaceutical industry digitization project.
Two chain pharmacy brands “TongJunGe Pharmacy” and “Taiji Pharmacy” have won titles of “China's Famous Commercial Enterprise” and “Top 100 Chain Pharmacy in China by Direct Sales Strength” several times， ranking 6th in the Top 100 Value List and ranking 8th in the Top 100 Comprehensive Strength List of 《China Drug Store》 in 2019-2020 . Taiji Group won second place in the "Comprehensive Statistics of China's OTC Drug Manufacturers in 2022". In March 2022, Taiji Group was approved as the first "National TCM Service Export Base" in Chongqing.
In 1998, Taiji Group worked with domestic and foreign universities to establish the first batch of post-doctoral workstations in China. In 1999, Taiji Groups Technology Center was recognized as a National Enterprise Technology Center. In recent years, Taiji Group has undertaken nearly 30 major special projects of the Ministry of Science and Technology, the National Development and Reform Commission and the Ministry of Industry and Information Technology, and more than 50 provincial projects. Taiji Group has successfully developed more than 40 new drugs, obtained more than 30 national new drug certificates, and won 3 China Patent Gold Awards. Taiji Group holds 247 valid authorized patents and a total of 1,240 drug approvals, including 692 approvals for TCM drugs, 548 approvals for chemical drugs, 741 approvals for drugs covered by medical insurance, and 368 approvals for essential drugs.
Taiji products cover six therapeutic areas, including digestive system and metabolic system drugs represented by Huo Xiang Zheng Qi Kou Fu Ye and Rosiglitazone Sodium Tablets; Respiratory system drugs represented by Ji Zhi Tang Jiang; Cardiovascular drugs represented by Dan Shen Kou Fu Ye；Anti-infective drugs represented by Ceftizoxime Sodium for Injection；Nervous system drugs represented by Tong Tian Kou Fu Ye and Morphine Hydrochloride Sustained-Release Tablets；Antitumor and immunomodulatory drugs represented by Paclitaxel Injection and Bu Shen Yi Shou Jiao Nang, as well as health products. Taiji products have a high market share. The brand and quality have won people's recognition and trust.
In terms of TCM production, Taiji Group owns China Time-Honored Brand "TongJunGe", and a number of national, provincial, municipal, district items of intangible cultural heritage such as the "TongJunGe traditional pill production technique", in addition to a syrup production line with an annual output of 100 million bottles, an oral solution production line with an annual output of 2 billion bottles, a TCM material pre-treatment workshop and extraction and concentration workshop with an annual output of 100,000 tons. In terms of chemical drug production, Taiji Group owns a designated manufacturer of stupefacient and psychotropic drugs in southwest China, which has advanced controlled slow release technology, rapid release technology, guttate pill and slow release guttate pill technologies. In terms of TCM decoction pieces production, we have an intelligent factory with an annual output of 1,500 tons of high-quality TCM decoction pieces.
Taiji Group has successfully built a large pharmaceutical sales system integrating pharmaceutical retail, hospital sales, retail terminal distribution, commercial distribution, pharmaceutical import and export, pharmaceutical e-commerce, TCM sales, 3rd-party pharmaceutical logistics and other services for more than 50,000 product specifications. By virtue of integrity, high quality and professional service, the retail business has won the trust of the public, with comprehensive competitiveness among the top drug vendors in Sichuan and Chongqing. Taiji Group has set up a number of distribution centers, with a total storage area of about 150,000 square meters, more than 200 vehicles for distribution and cold chain distribution. The distribution capacity reaches more than 100,000 terminals. Taiji Group’s subsidiary such as Tong Jun Ge Co., Ltd., is a strategic reserve unit for medical supplies in Chongqing; Tong Jun Ge Logistics & Distribution Co., Ltd., is the first qualified 3rd-party logistics enterprise for medicine and medical instruments in Chongqing, with a designed warehouse capacity of 1 million pieces and an annual throughput capacity of 20 million pieces.
Focusing on high-quality TCM materials, Taiji Group insists on “genuine planting, full traceability, follow the requirements of “sulfur-free, aflatoxin-free, pollution-free, whole-process traceability and six unification”, and control the quality of TCM materials throughout the production process through "Taiji TCM Agriculture Full Quality Traceability Platform". Taiji Group has built more than 100,000 mu of standard planting bases for TCM materials. The planting scale of Pinellia ternata, Fagopyrum cymosum, Radix Peucedani and other single varieties is leading in the industry. We have undertaken 5 national TCM material planting and scientific research projects and 8 provincial key scientific and technological research projects. Our company has been rated as a "National Key Leading Enterprise for Agricultural Industrialization" for several times.
Closely following the Belt and Road Initiative, Taiji Group actively explores overseas markets for TCM and promotes TCM culture. Taiji product series with 30 product specifications, including Huo Xiang Zheng Qi Kou Fu Ye、Ji Zhi Tang Jiang、Bu Shen Yi Shou Jiao Nang、Taiji E Jiao、Dan Shen Kou Fu Ye、Chuan Long Gu Ci Pian、Liu Wei Di Huang Wan (Concentrated Pills), have been registered in dozens of countries and territories, such as Singapore, Malaysia, Indonesia, Thailand, the United States, Canada, Russia, Pakistan, with 66 registration numbers.
Big Health Industry
Taiji Group actively implements the "Healthy China" strategy, speeds up its pace in the big health industry, combines TCM culture with ecological health preservation, and creates health products and new ecological health care projects. Taiji health products include “TAIJI”Shampoo,TAIJIShower Gel, Lycopene Soft Capsule and so on. We are forming a new pattern in the big health industry chain through a number of new concept health care projects, such as Taiji Health Care Industry Base (Sinopharm International Life and Health City), Wuling Mountain National Forest Park and Kangding Cordyceps Base.
Unshaken Original Aspiration, Constant Business Progress
Guided by the core value of “All for Health,Health for All”, Taiji Group keeps the original aspiration of “TCM for Huaxia, Taiji for People” in mind, follows Sinopharm's overall development strategy of innovation-driven full life cycle, full industry chain and full ecosystem with "four beams and eight pillars, top 100 + 100 trillion", stick to the target position of "stronger, better and bigger pharmaceutical and health core business". Taiji Group innovates on heritage, seek for greater perfection, constantly promote the modernization of TCM, strives to build a world-class TCM enterprise, promote the internationalization of TCM., and contributes to the building of a healthy China and the realization of the Chinese dream of the great rejuvenation of the Chinese nation.